ABSTRACT
Benign prostatic hyperplasia (BPH) is the most frequently diagnosed neoplastic disease in the aging male, affecting approximately 85% of all men over 50 years of age. By the ninth decade of life, 50% of all American men require treatment for symptomatic relief of the lower urinary tract symptoms (LUTS) associated with BPH. Clinically, BPH is characterized by prostatic enlargement and the accompanying symptoms of progressive bladder outlet obstruction.
